RxDoctor Payments Data

Adam Hy, DO

Family Medicine · Rowland Heights, CANPI 1982640413

Payments from drug & device makers

$2,757in general payments, 2019–2025

Across 71 payments — averaging $38.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$272
  • Amgen$260
  • Amarin Pharma, Inc.$225
  • Lilly USA, LLC$159
  • Exact Sciences$147
  • plus $675 from 10 others

What the payments were for

  • Food & beverage$2,72599%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,757 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$74,744
Medicare patients
72
Services billed
2,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate49$32,120
FarxigaDapagliflozin Propanediol37$29,765
KerendiaFinerenone21$15,475
JardianceEmpagliflozin19$13,132
Diclofenac Sodium19$12,283
DapagliflozinDapagliflozin Propanediol11$8,318
GemtesaVibegron12$7,913
RestasisCyclosporine12$7,564
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,678
Janumet XrSitagliptin Phos/Metformin Hcl12$3,303
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,422
Atorvastatin Calcium193$1,795
Metformin Hcl180$1,196
Morphine Sulfate ErMorphine Sulfate27$1,118
Losartan Potassium118$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,019$29,76537 claims
BayerKerendia$46$15,47521 claims
Boehringer IngelheimJardiance$97$13,13219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Rowland Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →